

## HPMS E-Mail

**Date:** December 15, 2023

**Subject:** Medicare Advantage and Prescription Drug Programs: Part C and Part D Explanation of Benefits, 30-Day Comment Period for Proposed Information Collection

On December 8, 2023, CMS posted a notice in the Federal Register (88 FR 85622) announcing the 30-day public comment period for the proposed information collection requirements associated with the MA and Part D Programs, Part C and Part D CY 2025 Explanation of Benefits.

The Centers for Medicare & Medicaid Services (CMS) requests renewal of this currently approved information collection, which includes substantive changes such as the addition of the burden associated with the Medicare Prescription Drug Program (Part D) Explanation of Benefits (EOB), which is currently approved through September 30, 2025 under OMB control number 0938-0964 (CMS-10141). The proposed changes to this information collection include other updates to the burden associated with Medicare Advantage (MA) and Part D EOBs, and updates to the Part D EOB to comply with the Part D benefit redesign provisions in section 11201 of the Inflation Reduction Act of 2022, Public L. 117-169 (IRA).

CMS encourages interested parties to review the Federal Register notice for the proposed Medicare Advantage and Prescription Drug Programs - Part C and Part D CY 2025 Explanation of Benefits information collection (CMS-10453, OMB 0938-1228), which is published at: <https://www.federalregister.gov/documents/2023/12/08/2023-27033/agency-information-collection-activities-submission-for-omb-review-comment-request>. Comments must be received by January 8, 2024, to be considered, and must be submitted as described in the Federal Register notice. The supporting statement and related documentation are available at: <https://www.cms.gov/regulations-and-guidance/legislation/paperworkreductionactof1995/pralisting/1719218337/cms-10453>.